Ginkgo Bioworks Holdings, Inc. (DNA) stock
Close on Nov 17, 2026Market cap $560.27MP/E –Yield –
Earnings
Ginkgo Bioworks's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Ginkgo Bioworks's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026after the close | $28.00M | -28.2% | -$0.64 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 5, 2026after the close | $20.00M | -60.0% | -$0.75 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026after the close | $19.00M | -60.7% | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026after the close | $33.00M | -25.0% | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025after the close | $39.00M | -56.2% | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025after the close | $50.00M | -10.7% | -$1.10 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 6, 2025after the close | $48.32M | +27.2% | -$1.68 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 25, 2025after the close | $44.00M | +25.7% | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024after the close | $89.00M | +61.8% | -$1.08 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024after the close | $56.00M | -30.9% | -$0.11 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024after the close | $38.00M | -53.1% | -$0.08 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 29, 2024after the close | $35.00M | -64.3% | -$0.11 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 8, 2023after the close | $55.00M | -16.7% | -$0.16 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 9, 2023after the close | $81.00M | -44.1% | -$0.09 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 10, 2023during market hours | $81.00M | -51.8% | -$0.11 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 1, 2023during market hours | $98.00M | -33.8% | -$0.10 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 14, 2022during market hours | $66.00M | -14.9% | -$0.41 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 15, 2022during market hours | $145.00M | – | -$0.41 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 16, 2022during market hours | $168.00M | – | -$0.37 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 28, 2022during market hours | $148.00M | – | -$1.10 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 15, 2021before the open | $77.60M | – | -$0.08 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Ginkgo Bioworks's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| total cash burnnon-GAAP | FY2026 | -$150.00M – -$125.00M | – | New | Nov 5, 2026 |
| total cash burnnon-GAAP | FY2026 | -$150.00M – -$125.00M | -$150.00M – -$125.00M | Reaffirmed | Aug 5, 2026 |
Guidance vs results
The last range Ginkgo Bioworks gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $167.00M – $187.00M | $170.32MΣ4Q | Within range |
Guidance history
Every forecast Ginkgo Bioworks put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | total cash burn | FY2026 | -$150.00M – -$125.00M | New |
| Aug 5, 2026 | total cash burn | FY2026 | -$150.00M – -$125.00M | Reaffirmed |
| May 7, 2026 | total cash burn | FY2026 | -$150.00M – -$125.00M | Reaffirmed |
| Feb 26, 2026 | total cash burn | FY2026 | -$150.00M – -$125.00M | New |
| Nov 6, 2025 | Total revenue | FY2025 | $167.00M – $187.00M | New |
| Nov 6, 2025 | Cell Engineering revenue | FY2025 | $117.00M – $137.00M | Lowered |
| Nov 6, 2025 | Biosecurity revenue | FY2025 | $40.00M | Lowered |
| Aug 7, 2025 | Biosecurity revenue | FY2025 | $40.00M | Lowered |
| Aug 7, 2025 | Cell Engineering revenue | FY2025 | $117.00M – $137.00M | Lowered |
| Aug 7, 2025 | Total revenue | FY2025 | $167.00M – $187.00M | Raised |
| May 6, 2025 | Biosecurity revenue | FY2025 | $50.00M | Lowered |
| May 6, 2025 | Cell engineering revenue | FY2025 | $117.00M – $137.00M | Lowered |
| May 6, 2025 | Total revenue | FY2025 | $167.00M – $187.00M | Raised |
| Feb 25, 2025 | Total revenue | FY2025 | $160.00M – $180.00M | New |
| Feb 25, 2025 | Cell Engineering revenue | FY2025 | $110.00M – $130.00M | Lowered |
| Feb 25, 2025 | Biosecurity revenue | FY2025 | $50.00M | Lowered |
| Nov 12, 2024 | Total revenue | FY2024 | $215.00M – $235.00M | Raised |
| Nov 12, 2024 | Cell Engineering services revenue | FY2024 | $165.00M – $185.00M | Lowered |
| Nov 12, 2024 | Biosecurity revenue | FY2024 | $50.00M | Lowered |
| Aug 8, 2024 | Total revenue | FY2024 | $170.00M – $190.00M | Raised |
| Aug 8, 2024 | Cell Engineering services revenue | FY2024 | $120.00M – $140.00M | Lowered |
| Aug 8, 2024 | Biosecurity revenue | FY2024 | $50.00M | Lowered |
| May 9, 2024 | new customer projects | FY2024 | 100 | Lowered |
| May 9, 2024 | Total revenue | FY2024 | $170.00M – $190.00M | Lowered |
| May 9, 2024 | Cell Engineering services revenue | FY2024 | $120.00M – $140.00M | Lowered |
| May 9, 2024 | Biosecurity revenue | FY2024 | $50.00M | Lowered |
| Feb 29, 2024 | new Cell Programs | FY2024 | 100 – 120 | New |
| Feb 29, 2024 | Total revenue | FY2024 | $215.00M – $235.00M | New |
| Nov 8, 2023 | new Cell Programs target | FY2023 | 80 – 85 | Lowered |
| Nov 8, 2023 | Total revenue | FY2023 | $250.00M – $260.00M | Raised |
| Aug 9, 2023 | new Cell Programs | FY2023 | 100 | Reaffirmed |
| Aug 9, 2023 | Total revenue | FY2023 | $245.00M – $260.00M | Raised |
| Aug 9, 2023 | Cell Engineering revenue | FY2023 | $145.00M – $160.00M | Lowered |
| Aug 9, 2023 | Biosecurity revenue | FY2023 | $100.00M | Lowered |
| May 10, 2023 | new Cell Programs | FY2023 | 100 | Reaffirmed |
| May 10, 2023 | Total revenue | FY2023 | $275.00M | Reaffirmed |
| May 10, 2023 | Cell Engineering revenue | FY2023 | $175.00M | Lowered |
| May 10, 2023 | Biosecurity revenue | FY2023 | $100.00M | Lowered |
| Mar 1, 2023 | new Cell Programs | FY2023 | 100 | New |
| Mar 1, 2023 | Total revenue | FY2023 | $275.00M | New |
| Nov 14, 2022 | new Cell Programs | FY2022 | 55 – 60 | Lowered |
| Nov 14, 2022 | Total revenue | FY2022 | $460.00M – $480.00M | Raised |
| Nov 14, 2022 | Foundry revenue | FY2022 | $150.00M – $170.00M | Lowered |
| Nov 14, 2022 | Biosecurity revenue | FY2022 | $310.00M | Raised |
| Aug 15, 2022 | new Cell Programs | FY2022 | 60 | Reaffirmed |
| Aug 15, 2022 | Total revenue | FY2022 | $425.00M – $440.00M | Raised |
| Aug 15, 2022 | Foundry revenue | FY2022 | $165.00M – $180.00M | Lowered |
| Aug 15, 2022 | Biosecurity revenue | FY2022 | $260.00M | Raised |
| May 16, 2022 | new Cell Programs | FY2022 | 60 | Reaffirmed |
| May 16, 2022 | Total revenue | FY2022 | $375.00M – $390.00M | Raised |
| May 16, 2022 | Foundry revenue | FY2022 | $165.00M – $180.00M | Lowered |
| May 16, 2022 | Biosecurity revenue | FY2022 | $210.00M | Raised |
| Mar 28, 2022 | new Cell Programs | FY2022 | 60 | New |
| Mar 28, 2022 | Total revenue | FY2022 | $325.00M – $340.00M | New |
| Mar 28, 2022 | Foundry revenue | FY2022 | $165.00M – $180.00M | Lowered |
| Mar 28, 2022 | Biosecurity revenue | FY2022 | $160.00M | Lowered |
| Nov 15, 2021 | incremental programs | Q4 FY2021 | 9 | New |
| Nov 15, 2021 | new programs | FY2021 | 30 | New |
| Nov 15, 2021 | total Foundry revenue | FY2021 | $100.00M | New |
| Nov 15, 2021 | Biosecurity revenue | FY2021 | $110.00M | Raised |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Ginkgo Bioworks filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Update
- Results
- Results
- Results
- Results
- Update
- Results
- Results
- Results
- Results
- Update
- Results
See a number that looks wrong?